Monday will be the first trading session after the 30 day wash period expired on Friday. The old shareholders that have been on the sidelines waiting to re-enter will be buying. ELN (in a similar situation last year) went up 65% in a few trading sessions after the wash period ended.
Once the share price moves above the $5.00 price level many funds will be able to purchase shares that are currently unable to do so. I also expect upgrades from one or two major brokerages will happen in the short term.
The company has $85,000,000 in cash, no debt, and three drugs in development with a potential market of over $6 billion. The company has funds to operate for the next 18 months.
Morgan Stanley, which had a $25.00 price target on the stock, said that one of the drugs could become the "Gold Standard" for treating enlarged prostrates. The potential market for that one drug alone is $3 billion.
The other drug treats pancreatic cancer and was just recommended by an independent committee to be allowed to proceed to phase 3 trials. This drug alone justifies a share price in excess of the current share price.
On June 1 the company received the formal letter from the F.D.A. and it is in the process of preparing its� response. At the Bank of America Health Care Conference the C.O.O. of Threshold stated that the company �fully expects� the trial to resume. The drug has already been approved in Europe and it is believed that the elevated liver enzymes are , in a woesrt case scenario simply a dosing issue and in the most likely scenario due to outside factors totally unrelated to the drug such as chronic alcoholism.
A partnership or a buyout is quite likely.
Visit "stockconsultant,com" and notice it now has a "100% bullish" summary rating on the stock with a short term price target of $5.36. Also it�s trade quality at 95% to the �upside� is the highest its� been since the drop in the share price.